Finally, oligoclonal cocktails of three [28,29] or six [30,31] antibodies against EGFR, HER2 and HER3 have an increased anti-tumor effect in experimental models, with blockade of the underlying extracellular signal-regulated kinase (ERK) and protein kinase B (AKT) signaling pathways and accelerated receptor degradation. The gene discussed is EGFR; the disease is neoplasm.